HER2+ Tumor Molecular Subtypes Predict Response to Dual HER2 Blockade [Clinical Trials]

Trastuzumab plus lapatinib achieves the highest response rates in HER2-enriched HER2+ breast tumors.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: Clinical Trials Source Type: research